FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951285627> ?p ?o ?g. }

• W2951285627 endingPage "215" @default.
• W2951285627 startingPage "207" @default.
• W2951285627 abstract "Objectives Targeted therapy (TT) is an effective treatment for advanced BRAFV600-mutated melanoma, but most patients eventually acquire resistance and progress. Here, we evaluated the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition. Methods Patients with metastatic melanoma progressing on combined BRAF + MEK inhibition and receiving second-line ICB between 2015 and 2019 in 9 tertiary referral centres were enrolled. Demographic and clinical data and blood counts of all patients were collected retrospectively. Results We identified 99 patients with stage IV melanoma receiving ICB (nivolumab, pembrolizumab [n = 39] or ipilimumab plus nivolumab [n = 60]) after progression on combined TT. The median progression-free survival was similar in the PD-1 and ipilimumab plus nivolumab group (2.6 months [95% confidence interval {CI}, 2.0–3.1] vs. 2.0 [95% CI, 1.4–2.6], p = 0.15). The objective response rate was 18.0% in the PD-1 and 15.0% in the ipilimumab plus nivolumab group (p = 0.70). The disease control rate was 25.7% for monotherapy and 18.3% for combined ICB (p = 0.39). The median overall survival was 8.4 months (95% CI, 5.1–11.7) for patients receiving PD-1 monotherapy and 7.2 months (95% CI, 5.2–9.1) for patients receiving ipilimumab plus nivolumab (p = 0.86). The latter was associated with a higher rate of treatment-related adverse events (AEs). No significant association of laboratory values or clinicopathological characteristics with response to second-line ICB was observed. Conclusions PD-1 monotherapy and combined ipilimumab plus nivolumab show similar activity and outcome in patients with melanoma resistant to BRAF + MEK inhibition. However, combined ipilimumab plus nivolumab was associated with a higher rate of treatment-related AEs compared with monotherapy." @default.
• W2951285627 created "2019-06-27" @default.
• W2951285627 creator A5001548963 @default.
• W2951285627 creator A5001568438 @default.
• W2951285627 creator A5007887862 @default.
• W2951285627 creator A5008750058 @default.
• W2951285627 creator A5017486762 @default.
• W2951285627 creator A5019175541 @default.
• W2951285627 creator A5025256131 @default.
• W2951285627 creator A5034365278 @default.
• W2951285627 creator A5037964605 @default.
• W2951285627 creator A5056227404 @default.
• W2951285627 creator A5057381405 @default.
• W2951285627 creator A5069095893 @default.
• W2951285627 creator A5076054848 @default.
• W2951285627 creator A5088390068 @default.
• W2951285627 date "2019-07-01" @default.
• W2951285627 modified "2023-10-01" @default.
• W2951285627 title "Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma" @default.
• W2951285627 cites W1557490668 @default.
• W2951285627 cites W1576116802 @default.
• W2951285627 cites W1834835434 @default.
• W2951285627 cites W2096387850 @default.
• W2951285627 cites W2097995306 @default.
• W2951285627 cites W2152897456 @default.
• W2951285627 cites W2166662937 @default.
• W2951285627 cites W2338494814 @default.
• W2951285627 cites W2397854274 @default.
• W2951285627 cites W2572266985 @default.
• W2951285627 cites W2620651944 @default.
• W2951285627 cites W2631627985 @default.
• W2951285627 cites W2746148521 @default.
• W2951285627 cites W2753432434 @default.
• W2951285627 cites W2761314488 @default.
• W2951285627 cites W2778738124 @default.
• W2951285627 cites W2794627893 @default.
• W2951285627 cites W2799363878 @default.
• W2951285627 cites W2809898840 @default.
• W2951285627 cites W2886076079 @default.
• W2951285627 cites W2917811217 @default.
• W2951285627 doi "https://doi.org/10.1016/j.ejca.2019.05.015" @default.
• W2951285627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31212163" @default.
• W2951285627 hasPublicationYear "2019" @default.
• W2951285627 type Work @default.
• W2951285627 sameAs 2951285627 @default.
• W2951285627 citedByCount "34" @default.
• W2951285627 countsByYear W29512856272019 @default.
• W2951285627 countsByYear W29512856272020 @default.
• W2951285627 countsByYear W29512856272021 @default.
• W2951285627 countsByYear W29512856272022 @default.
• W2951285627 crossrefType "journal-article" @default.
• W2951285627 hasAuthorship W2951285627A5001548963 @default.
• W2951285627 hasAuthorship W2951285627A5001568438 @default.
• W2951285627 hasAuthorship W2951285627A5007887862 @default.
• W2951285627 hasAuthorship W2951285627A5008750058 @default.
• W2951285627 hasAuthorship W2951285627A5017486762 @default.
• W2951285627 hasAuthorship W2951285627A5019175541 @default.
• W2951285627 hasAuthorship W2951285627A5025256131 @default.
• W2951285627 hasAuthorship W2951285627A5034365278 @default.
• W2951285627 hasAuthorship W2951285627A5037964605 @default.
• W2951285627 hasAuthorship W2951285627A5056227404 @default.
• W2951285627 hasAuthorship W2951285627A5057381405 @default.
• W2951285627 hasAuthorship W2951285627A5069095893 @default.
• W2951285627 hasAuthorship W2951285627A5076054848 @default.
• W2951285627 hasAuthorship W2951285627A5088390068 @default.
• W2951285627 hasConcept C121608353 @default.
• W2951285627 hasConcept C126322002 @default.
• W2951285627 hasConcept C143998085 @default.
• W2951285627 hasConcept C197934379 @default.
• W2951285627 hasConcept C2777658100 @default.
• W2951285627 hasConcept C2777701055 @default.
• W2951285627 hasConcept C2780030458 @default.
• W2951285627 hasConcept C2780057760 @default.
• W2951285627 hasConcept C2780739268 @default.
• W2951285627 hasConcept C2781433595 @default.
• W2951285627 hasConcept C3019894029 @default.
• W2951285627 hasConcept C44249647 @default.
• W2951285627 hasConcept C502942594 @default.
• W2951285627 hasConcept C71924100 @default.
• W2951285627 hasConcept C90924648 @default.
• W2951285627 hasConceptScore W2951285627C121608353 @default.
• W2951285627 hasConceptScore W2951285627C126322002 @default.
• W2951285627 hasConceptScore W2951285627C143998085 @default.
• W2951285627 hasConceptScore W2951285627C197934379 @default.
• W2951285627 hasConceptScore W2951285627C2777658100 @default.
• W2951285627 hasConceptScore W2951285627C2777701055 @default.
• W2951285627 hasConceptScore W2951285627C2780030458 @default.
• W2951285627 hasConceptScore W2951285627C2780057760 @default.
• W2951285627 hasConceptScore W2951285627C2780739268 @default.
• W2951285627 hasConceptScore W2951285627C2781433595 @default.
• W2951285627 hasConceptScore W2951285627C3019894029 @default.
• W2951285627 hasConceptScore W2951285627C44249647 @default.
• W2951285627 hasConceptScore W2951285627C502942594 @default.
• W2951285627 hasConceptScore W2951285627C71924100 @default.
• W2951285627 hasConceptScore W2951285627C90924648 @default.
• W2951285627 hasLocation W29512856271 @default.
• W2951285627 hasLocation W29512856272 @default.
• W2951285627 hasOpenAccess W2951285627 @default.

• next